BB Biotech (BION)

Business description

BION is a Switzerland-domiciled investment company, targeting attractive long-term returns from predominantly mid-/large-cap biotech companies with established product portfolios (sales and earnings) and promising pipeline candidates. It is benchmarked against the NASDAQ Biotech Index, but is managed bottom-up with a concentrated 20-35 stock portfolio.

Stock data

Market cap.CHF3698m
Last closeCHF66.75
High / Low (52 weeks)CHF67.8 / CHF44.5
Stock market listingSW, IM
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamInvestment Companies
SectorInvestment Companies

Other companies in sector Show

Aberdeen New Dawn Investment Trust Aberdeen New Thai Investment Trust
Aberdeen Private Equity Fund Aberdeen UK Tracker Trust
AcenciA Debt Strategies Acorn Income Fund
Adamas Finance Asia Alliance Trust
Altamir SCA Amphion Innovations
Aurelius Bailador Tech Investments
Bankers Investment Trust (The) BlackRock Greater Europe Investment Trust
BlackRock Hedge Selector BlackRock Latin American Inv. Trust
British Portfolio Trust Brunner Investment Trust (The)
Canadian General Investments Carador Income Fund
Charles Stanley Circle Property
City Natural Resources Conversus Capital
CQS Rig Finance Fund CVC Credit Partners European Opps
Detour Gold Deutsche Beteiligungs
Dexion Commodities Diverse Income Trust (The)
DouglasBay Capital Dunedin Enterprise Investment Trust
DW Catalyst Fund Edinburgh Worldwide Investment Trust (The)
European Assets Trust European Investment Trust (The)
F&C Managed Portfolio Income F&C Managed Portfolio Trust
F&C US Smaller Companies Fidelity China Special Situations
Fidelity European Values Finsbury Growth & Income Trust
Foreign & Colonial Investment Trust Gartmore Growth Opportunities
Gartmore Irish Growth Fund Geiger Counter Limited
GLI Alternative Finance Global Resources Investment Trust
Golden Prospect Precious Metals Hansa Trust (HAN)
HarbourVest Global Private Equity HarbourVest Senior Loans Europe
HBM Healthcare Investments Heliad Equity Partners
Henderson Alternative Strategies Trust Henderson Far East Income
Henderson Global Trust Henderson Global Trust
Henderson International Income Trust HSBC Infrastructure Company
Infrastructure India International Biotechnology Trust
Invesco Asia Trust Invesco Income Growth Trust
Is Private Equity JP Morgan Private Equity Limited
JPMorgan Brazil Investment Trust JPMorgan European Smaller Companies Trust
JPMorgan Global Convertibles Income Fund JPMorgan Global Growth & Income
JPMorgan Indian Investment Trust Jupiter Green Investment Trust
Jupiter UK Growth Investment Trust Jupiter US Smaller Companies
JZ Capital Partners Limited Lazard World Trust Fund
Leaf Clean Energy Company LMS Capital
Lowland Investment Company LPEQ
Martin Currie Asia Unconstrained Trust Martin Currie Global Portfolio Trust
Middlefield Canadian Income Miton Global Opportunities
Miton Income Opportunities Trust New City Energy
Ocean Wilsons Holdings Pacific Assets Trust
Phaunos Timber Fund Polar Capital Global Healthcare Trust
PXP Vietnam Fund Qatar Investment Fund
Rathbone Brothers RENN Universal Growth Investment Trust
Schroder AsiaPacific Fund Schroder Global Real Estate Securities
ScotGems Scottish Oriental Smaller Companies
Securities Trust of Scotland Seneca Global Income & Growth Trust
Sigma Capital Group Standard Life Equity Income Trust
Standard Life Investments Property Income Trust Standard Life Private Equity Trust
Standard Life UK Smaller Companies Strategic Equity Capital
Taiwan Fund (The) Templeton Emerging Markets Investment Trust
Tetragon Financial Group The Biotech Growth Trust
The Law Debenture Corporation The Merchants Trust
The North American Income Trust The Scottish Investment Trust
Tiso Blackstar Group TR European Growth trust
UK Commercial Property Trust Utilico Emerging Markets
Vietnam Enterprise Investments Vietnam Holding Asset Management
Vietnam Infrastructure Fund VinaCapital Vietnam Opportunity Fund
VinaLand Vision Opportunity China Fund
WAM Active WAM Capital
WAM Research Witan Investment Trust
Witan Pacific Investment Trust Worldwide Healthcare Trust
YFM Equity Partners

Company news

Bb Biotech Ag Stake in Regeneron Pharmaceuticals (REGN) Has Cut by $31.92 ...

Fri, 20 Oct 2017 19:07:30 GMT

Neurocrine Biosciences (NBIX) Shareholder Bb Biotech Ag Lifted Holding; As ...

Fri, 20 Oct 2017 19:07:30 GMT

BB BIOTECH AG – Ord-Shs (BBZA.DE) Technicals Reveal Strong Momentum Building

Fri, 20 Oct 2017 10:29:16 GMT

Celgene (CELG) Market Value Declined While Bb Biotech Ag Has Decreased Its ...

Thu, 19 Oct 2017 16:41:09 GMT

Trading Watch: Reviewing the Numbers for BB Biotech AG (SWX:BION)

Fri, 20 Oct 2017 14:37:30 GMT

Investment summary

BB Biotech (BION) is a long-established investor in biotech innovation, offering access to a concentrated portfolio of c 30 companies covering a range of therapeutic areas. It seeks to provide long-term capital growth, but also offers a yield of c 5% as a result of a capital distribution policy adopted in 2012. Performance has been strong both over the long term and more recently, with the fund ranking first among peers (in Swiss franc terms) over one and five years, and also outperforming the benchmark NASDAQ Biotechnology Index over one, three, five and 10 years. Although biotech and healthcare stocks may continue to see some near-term share price volatility as the direction of US policy becomes clearer, BION’s managers point to lower-than-average biotech valuations as a source of support.

Last updated on 27/02/2017

Latest video

Bitesize Briefings - BB Biotech

Key management

Prof. Dr. Thomas Szucs, Chairman
Daniel Koller, Head of Management Team
Claude Mikkelsen, Director of IR
Dr. Silvia Schanz , Investor Relations

Company address

Seestrasse 16
Postfach
8700 Kusnacht / Zurich
Germany
+41 44 267 67 00
View website